title: Effects of SAHA on proliferation and apoptosis of hepatocellular carcinoma cells and hepatitis B virus replication.
abstract: OBJECTIVE
  To investigate the effects of suberoylanilide hydroxamic acid (SAHA) on proliferation and apoptosis of a human hepatocellular carcinoma cell line (HepG2.2.15) and hepatitis B virus (HBV) replication.
  
  
  METHODS
  HepG2.2.15 cells were treated with different concentrations of SAHA. Cell morphology was examined by confocal laser scanning microscopy, and cell proliferation was determined using a MTT colorimetric assay. Flow cytometry was used to detect apoptosis and determine cell cycle phase, while hepatitis B surface antigen and hepatitis B e antigen content were measured using chemiluminescence. Reverse transcription polymerase chain reaction was performed to measure HBV DNA in cell lysate.
  
  
  RESULTS
  Cell proliferation rates were significantly reduced by the addition of SAHA. The inhibitory effect of SAHA on cell proliferation was both time- and dose-dependent. After 24 h of treatment with SAHA, the early cell apoptotic rate increased from 3.25% to 21.02% (P = 0.041). The proportion of G₀/G₁ phase cells increased from 50.3% to 65.3% (P = 0.039), while that of S phase cells decreased from 34.9% to 20.6% (P = 0.049). After 48 h of treatment, hepatitis B surface antigen and hepatitis B e antigen content increased from 12.33 ± 0.62 to 25.42 ± 2.67 (P = 0.020) and 28.92 ± 1.24 to 50.48 ± 1.85 (P = 0.026), respectively. Furthermore, HBV DNA content increased from 4.54 ± 0.46 to 8.34 ± 0.59 (P = 0.029).
  
  
  CONCLUSIONS
  SAHA inhibits HepG2.2.15 cell proliferation, promotes apoptosis, and stimulates HBV replication. In combination with anti-HBV drugs, SAHA may potentially be used cautiously for treatment of hepatocellular carcinoma.
authors: Department of Gastroenterology, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, Liaoning Province, China. wych_1648@126.com
authors: Ying-Chun
authors: YC
authors: Wang
authors: Xu
authors: X
authors: Yang
authors: Lan-Hua
authors: LH
authors: Xing
authors: Wei-Zong
authors: WZ
authors: Kong
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000821:virology; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D048430:Cell Shape / Q000187:drug effects; D004261:DNA Replication / Q000187:drug effects; D004279:DNA, Viral / Q000096:biosynthesis / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D056945:Hep G2 Cells; D006514:Hepatitis B Surface Antigens / Q000378:metabolism; D006513:Hepatitis B e Antigens / Q000378:metabolism; D006515:Hepatitis B virus / Q000187:drug effects* / Q000254:growth & development / Q000276:immunology; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000473:pathology* / Q000821:virology; D013997:Time Factors; D014779:Virus Replication / Q000187:drug effects*; D000077337:Vorinostat
chemical_list: D000970:Antineoplastic Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat
keywords: HepG2.2.15 cells; Hepatitis B virus; Human hepatocellular carcinoma; Suberoylanilide hydroxamic acid
references: World J Gastroenterol. 2011 Oct 14;17(38):4258-70
references: 22090781
references: Blood. 2009 Jul 9;114(2):380-93
references: 19383971
references: Cancer Cell. 2003 Jul;4(1):13-8
references: 12892709
references: Zhonghua Gan Zang Bing Za Zhi. 2005 May;13(5):324-5
references: 15918962
references: Int J Cancer. 2011 Apr 15;128(8):1793-803
references: 20549706
references: Lancet Oncol. 2001 Sep;2(9):533-43
references: 11905707
references: Oncogene. 2007 Aug 13;26(37):5541-52
references: 17694093
references: Int J Oncol. 2011 Mar;38(3):807-12
references: 21170509
references: J Cell Mol Med. 2008 Apr;12(2):607-21
references: 18419600
references: Biochem Pharmacol. 2009 Sep 1;78(5):486-94
references: 19445901
references: J Proteome Res. 2010 Sep 3;9(9):4554-64
references: 20812760
references: Cancer Sci. 2011 Feb;102(2):343-50
references: 21159061
references: J Biol Chem. 2006 Apr 14;281(15):10508-15
references: 16476732
references: N Engl J Med. 2004 Oct 7;351(15):1567-70
references: 15470221
references: Expert Opin Investig Drugs. 2002 Dec;11(12):1695-713
references: 12457432
references: Blood. 2007 Jan 1;109(1):31-9
references: 16960145
references: Biochem Pharmacol. 2008 Jul 1;76(1):120-7
references: 18495085
references: Leuk Res. 2008 Sep;32(9):1382-92
references: 18394702
references: Am J Transl Res. 2011 Feb;3(2):166-79
references: 21416059
references: Cancer Res. 2011 Jan 15;71(2):454-62
references: 21224363
references: Nat Rev Drug Discov. 2002 Apr;1(4):287-99
references: 12120280
references: Ai Zheng. 2002 May;21(5):480-3
references: 12452036
references: Oncol Rep. 2008 Nov;20(5):1249-56
references: 18949429
references: Mol Cancer Ther. 2002 Sep;1(11):937-41
references: 12481415
references: Zhonghua Gan Zang Bing Za Zhi. 2011 Jan;19(1):44-7
references: 21272458
references: Int J Cancer. 2011 Jan 15;128(2):460-72
references: 20309941
references: Biochim Biophys Acta. 2010 Apr;1802(4):396-405
references: 20079433